Market Overview - The Hong Kong stock market experienced a decline for the second consecutive day, with all three major indices falling over 1%. The Hang Seng Index closed down 1.27% at 25,201.76 points, with a total turnover of HKD 371.376 billion [1] - The Hang Seng China Enterprises Index dropped 1.4% to 9,020.26 points, while the Hang Seng Tech Index fell 1.47% to 5,697.53 points [1] Blue Chip Performance - Nongfu Spring (09633) led the blue-chip stocks, rising 7.11% to HKD 50.3, contributing 10.53 points to the Hang Seng Index. The company reported a revenue of RMB 25.622 billion for the first half of 2025, a year-on-year increase of 15.56% [2] - Other notable blue-chip movements included Zhongsheng Holdings (00881) up 1.96%, China Hongqiao (01378) up 1.12%, while China Resources Mixc Lifestyle (01209) fell 9.08% and CSPC Pharmaceutical Group (01093) dropped 6.36% [2] Sector Highlights - Large tech stocks generally declined, with Tencent down 1.72% and Xiaomi down 0.56%. However, AI concept stocks surged following the State Council's release of the "Artificial Intelligence+" action plan, with SenseTime rising over 14% [3] - The AI action plan aims for over 70% application penetration of new intelligent terminals and intelligent entities by 2027, marking a shift towards deep integration with the real economy [3] Brokerage Stocks - Chinese brokerage stocks faced significant declines, with Shenwan Hongyuan (06806) down 6.02%, Dongfang Securities (03958) down 5.78%, and CITIC Securities (06030) down 4.11% [4] - The recent surge in the Shanghai Composite Index and trading volume indicates strong market sentiment, but there are signals of potential adjustments if volatility increases [4] Pharmaceutical Sector - The sentiment in the pharmaceutical sector remained low, with notable declines in stocks such as Connaught (02162) down 8.59% and King’s Flair International (01548) down 7.42% [4] Innovation Drug Sector - Guotou Securities reported that the current market capitalization of the innovative drug sector reflects a neutral expectation, with improvements in the domestic market expected to lead to profitability by 2026 [5] - The sector is anticipated to benefit from several catalysts in the second half of the year, including medical insurance negotiations and academic conferences [5] Notable Stock Movements - Lianyi Technology (09959) surged 23.21% to HKD 2.76 after announcing a share buyback plan [7] - Lens Technology (06613) reached a new high, rising 7.78% to HKD 27.98, driven by strong growth prospects and expected benefits from Apple's new products [8] - COSCO Shipping International (00517) reported a revenue of HKD 1.934 billion for the first half of 2025, a 10.3% year-on-year increase, with a profit attributable to shareholders of HKD 488 million, up 25.6% [9] - NIO (09866) rose 4.26% to HKD 51.65, supported by strong orders for new vehicle models [10] - Country Garden Services (06098) fell 11.11% after reporting a 30.8% decline in profit attributable to shareholders [11]

Market Overview - The Hong Kong stock market experienced a decline for the second consecutive day, with all three major indices falling over 1%. The Hang Seng Index closed down 1.27% at 25,201.76 points, with a total turnover of HKD 371.38 billion [1] - The short-term liquidity in the Hong Kong market is lagging, but it has structural advantages in the long term. Key characteristics of the market this year include stronger structure compared to indices and continuous rotation of leading sectors [1] Blue Chip Performance - Nongfu Spring (09633) led the blue-chip stocks, rising 7.11% to HKD 50.3, contributing 10.53 points to the Hang Seng Index. The company reported a revenue of RMB 25.622 billion for the first half of 2025, a year-on-year increase of 15.56% [2] - Other notable blue-chip movements included Zhongsheng Holdings (00881) up 1.96%, China Hongqiao (01378) up 1.12%, while China Resources Mixc Lifestyle (01209) fell 9.08%, and CSPC Pharmaceutical Group (01093) dropped 6.36% [2] Sector Highlights - Large technology stocks generally declined, with Tencent down 1.72% and Xiaomi down 0.56%. However, AI concept stocks surged following the State Council's release of the "Artificial Intelligence+" action plan, with SenseTime rising over 14% [3] - The AI action plan aims for over 70% application penetration of new intelligent terminals and entities by 2027, marking a shift towards deep integration with the real economy [3] - Chinese brokerage stocks faced significant declines, with Shenwan Hongyuan down 6.02% and Dongfang Securities down 5.78% [4] - The pharmaceutical sector showed low sentiment, with notable declines in stocks like Kangnuo Ya-B (02162) down 8.59% and King’s Flair International (01548) down 7.42% [4] Notable Stock Movements - Lianyi Technology-W (09959) saw a strong increase of 23.21% after announcing a share buyback plan of at least USD 80 million [7] - Lens Technology (06613) reached a new high, rising 7.78% due to strong growth prospects and expected benefits from Apple's upcoming foldable phone [7] - COSCO Shipping International (00517) reported a revenue of HKD 1.934 billion for the first half of 2025, a 10.3% year-on-year increase, with a profit attributable to shareholders of HKD 488 million, up 25.6% [8] - NIO-SW (09866) rose 4.26% as strong orders for new models are expected to drive stock price increases [9] - Country Garden Services (06098) fell 11.11% after reporting a 30.8% decline in profit attributable to shareholders despite a 10.2% increase in revenue [10]

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) fell over 7% towards the end of trading, reflecting market concerns following the release of disappointing interim results, with a significant decline in revenue and profit [1] Financial Performance - CSPC Pharmaceutical reported total revenue of 13.273 billion RMB for the first half of the year, a year-on-year decrease of 18.5% [1] - The profit attributable to the company's owners was 2.548 billion RMB, down 15.64% year-on-year [1] Market Reaction - The stock price dropped by 6.45% to 9.7 HKD, with a trading volume of 2.213 billion HKD [1] - The market has reacted negatively to the company's second-quarter performance, which fell short of expectations, particularly in the oncology and neurology business lines [1] Analyst Insights - According to a report from CMB International, the company's revenue and net profit in Q2 were below expectations, indicating structural declines in key business areas [1] - The firm downgraded its sales and net profit forecasts for 2025 to 2026 due to weak core business performance and overly optimistic business development expectations [1] - The rating was adjusted to "Neutral," with the target price reduced from 12.9 HKD to 9.3 HKD [1] Future Outlook - The future prospects of CSPC Pharmaceutical are seen as dependent on its commercial collaboration strategy and the commercialization of its pipeline [1] - Market attention is focused on its key asset, SYS6010, but past performance in the development of Class 1 innovative drugs suggests that the company is lagging behind other large pharmaceutical and biotech firms in China [1]

招商证券国际发布研报称，石药集团(01093)今年二季度收入及净利润均不及预期，反映肿瘤和神经系 统业务线的结构性下行，管理层重申EGFR ADC产品(CPO301/SYS6010)为潜在商业发展(BD)催化剂， 但该行认为市场已消化相关预期。招商证券国际下调集团2025至2026年销售及净利润预测，因公司核心 业务表现乏力及BD预期过高，下调评级至"中性"和目标价至9.3港元(原本12.9港元)。 该行表示，展望未来，石药集团的前景取决于商业合作战略及后期管线商业化情况。市场关注其关键资 产SYS6010。然而，回顾石药过去在1.1类创新药物研发的表现，该行认为其在管线临床进展上落后于 中国其他大型制药及部分生物药公司。 鉴于核心业务环比持续下滑，招商证券国际下调集团今明两年的收入和净利润预测，以反映增长及盈利 前景的短期压力，预计2025财年经历深度调整后，2026财年收入将趋于稳定。目标价调整反映盈利调整 及拆股因素，该行根据成药、管线及传统原料药业务的SOTP估值调整目标价，新目标价为9.3港元，分 别对应今明两年19.4倍、17.9倍市盈率。 ...

Core Viewpoint - The stock price of CSPC Pharmaceutical Group (01093) fell over 7% towards the end of trading, reflecting market concerns following the release of disappointing interim results for the first half of the year [1] Financial Performance - Total revenue for the first half of the year was 13.273 billion RMB, a year-on-year decrease of 18.5% [1] - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year [1] Market Reaction - The stock price dropped by 6.45% to 9.7 HKD, with a trading volume of 2.213 billion HKD [1] - The decline in stock price indicates that the market has reacted negatively to the company's financial performance and outlook [1] Analyst Insights - According to a report from CMB International, the second quarter revenue and net profit of CSPC Pharmaceutical did not meet expectations, indicating structural declines in the oncology and neurology business lines [1] - The management reiterated that the EGFR ADC product could be a potential catalyst for business development, but the market has already priced in these expectations [1] - CMB International has lowered its sales and net profit forecasts for 2025 to 2026 due to weak core business performance and overly optimistic business development expectations [1] Future Outlook - The future prospects of CSPC Pharmaceutical depend on its commercial cooperation strategy and the commercialization of its pipeline [1] - Market attention is focused on its key asset SYS6010, but the company has lagged behind other large pharmaceutical and biotech companies in clinical progress for Class 1 innovative drugs [1]

智通财经APP获悉，招商证券国际发布研报称，石药集团(01093)今年二季度收入及净利润均不及预期， 反映肿瘤和神经系统业务线的结构性下行，管理层重申EGFR ADC产品(CPO301/SYS6010)为潜在商业 发展(BD)催化剂，但该行认为市场已消化相关预期。招商证券国际下调集团2025至2026年销售及净利 润预测，因公司核心业务表现乏力及BD预期过高，下调评级至"中性"和目标价至9.3港元(原本12.9港 元)。 该行表示，展望未来，石药集团的前景取决于商业合作战略及后期管线商业化情况。市场关注其关键资 产SYS6010。然而，回顾石药过去在1.1类创新药物研发的表现，该行认为其在管线临床进展上落后于 中国其他大型制药及部分生物药公司。 鉴于核心业务环比持续下滑，招商证券国际下调集团今明两年的收入和净利润预测，以反映增长及盈利 前景的短期压力，预计2025财年经历深度调整后，2026财年收入将趋于稳定。目标价调整反映盈利调整 及拆股因素，该行根据成药、管线及传统原料药业务的SOTP估值调整目标价，新目标价为9.3港元，分 别对应今明两年19.4倍、17.9倍市盈率。 ...

恒生指数、恒生科技指数双双转跌，华润万象生活跌超8.5％，翰森制药、石药集团、申洲国际、李宁 等均跌4％。 (本文来自第一财经) ...

Core Viewpoint - The Hong Kong stock market for innovative drugs is experiencing a pullback, with the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index down by 2.31%, and most constituent stocks also declining [1]. Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug ETF (520880) opened high but fell by 1.97% during the session, indicating a downward trend despite a positive buying attitude reflected in a real-time premium rate of 0.4% [1]. - Year-to-date until July 31, the Hang Seng Hong Kong Stock Connect Innovative Drug Selective Index has increased by 101.58%, outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 78.08 and 79.53 percentage points respectively [5]. Group 2: Future Outlook - Despite recent volatility in innovative drug sentiment, there are continuous catalysts for the sector, including mid-year performance reports, industry conference data, potential business development transactions, and the advancement of commercial insurance directories [3]. - With expectations of interest rate cuts in the U.S., the valuation framework for innovative drugs is likely to improve [3]. - The improvement in liquidity narratives suggests that the Hong Kong stock market may experience a phase of rebound, narrowing the gap with the rapidly rising A-share market [3]. Group 3: Investment Strategy - The current earnings forecast rate for the Hong Kong stock market is at its highest since 2022, suggesting a favorable environment for investment [3]. - It is recommended to focus on innovative drugs first, followed by the internet sector, and finally new consumption, as the latter awaits macroeconomic and profit turning points [3].

Group 1 - The Hong Kong innovative drug concept stocks have declined, with companies such as 3SBio and Hansoh Pharmaceutical dropping over 4%, while Innovent Biologics, CSPC Pharmaceutical Group, and China National Pharmaceutical Group fell over 3% [1] - The Hang Seng Innovative Drug ETF has decreased nearly 2% due to market influences [1] Group 2 - Several ETFs related to innovative drugs have shown declines, with specific prices and percentage drops noted, such as the Hang Seng Innovative Drug ETF at 1.597, down 1.90% [2] - A brokerage firm indicated that the collection of chemical drugs has completed ten batches, with the new batch increasing quality requirements and reflecting a reduction in "involution," leading to a diminishing marginal impact [2] - The Pharma collection is gradually clearing out, entering a period of innovative transformation and harvest, with favorable medical insurance policies expected to support rapid growth of innovative drugs [2]